Media stories about Neuralstem (NASDAQ:CUR) have been trending somewhat positive on Tuesday, Accern reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Neuralstem earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news coverage about the company an impact score of 47.0380005563562 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Neuralstem (NASDAQ CUR) opened at $1.12 on Tuesday. Neuralstem has a 1 year low of $0.88 and a 1 year high of $6.60.
COPYRIGHT VIOLATION NOTICE: This article was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2017/12/05/neuralstem-cur-receives-daily-media-sentiment-rating-of-0-09.html.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.